Randomized multicenter phase III study of epirubicin/paclitaxel versus epirubicin/cyclophosphamide in first-line treatment of metastatic breast cancer:: A study of the AGO Breast Cancer Study Group

被引：0
|
作者：
Lück, HJ [1 ]
Thomssen, C [1 ]
Kuhn, W [1 ]
Eidtmann, H [1 ]
du Bois, A [1 ]
Möbus, V [1 ]
Untch, M [1 ]
Jackisch, C [1 ]
Olbricht, S [1 ]
Schröder, W [1 ]
Richter, B [1 ]
Bauknecht, T [1 ]
Köhler, C [1 ]
Schulz, R [1 ]
von Minckwitz, G [1 ]
Blohmer, J [1 ]
机构：
[1] Med Hsch Hannover, Frauenklin, Hannover, Germany
来源：
SEMINARS IN ONCOLOGY | 1999年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8 / 8
页数：1
相关论文
共 50 条
  • [1] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Hans-Joachim Lück
    Andreas Du Bois
    Sibylle Loibl
    Iris Schrader
    Jens Huober
    Volker Heilmann
    Matthias Beckmann
    Ann Stähler
    Christian Jackisch
    Michael Hubalek
    Barbara Richter
    Elmar Stickeler
    Holger Eidtmann
    Christoph Thomssen
    Michael Untch
    Kerstin Wollschläger
    Tibor Schuster
    Gunter von Minckwitz
    [J]. Breast Cancer Research and Treatment, 2013, 139 : 779 - 787
  • [2] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Lueck, Hans-Joachim
    Du Bois, Andreas
    Loibl, Sibylle
    Schrader, Iris
    Huober, Jens
    Heilmann, Volker
    Beckmann, Matthias
    Staehler, Ann
    Jackisch, Christian
    Hubalek, Michael
    Richter, Barbara
    Stickeler, Elmar
    Eidtmann, Holger
    Thomssen, Christoph
    Untch, Michael
    Wollschlaeger, Kerstin
    Schuster, Tibor
    von Minckwitz, Gunter
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 779 - 787
  • [3] Phase III-multicenter trial epirubicin-paclitaxel vs. epirubicin-cyclophosphamide as first-line therapy of metastatic breast cancer - an AGO study protocol
    Schroeder, W
    Luck, HJ
    Thomssen, C
    Mobus, V
    Kuhn, W
    von Minckwitz, G
    Untch, M
    Jackisch, C
    Kohler, G
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 12 - 12
  • [4] Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: A dose escalation study
    Bonneterre, J
    Tubiana-Hulin, M
    Catimel, G
    [J]. ONCOLOGY, 2004, 66 (03) : 185 - 191
  • [5] Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC):: A prospective, randomized multicentre phase III study of the AGO breast cancer study group.
    Lueck, H.
    Minckwitz, G. V.
    Du Bois, A.
    Schrader, I.
    Huober, J.
    Heilmann, V.
    Beckmann, M.
    Stähle, A.
    Jackisch, C.
    Marth, C.
    Richter, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 7S - 7S
  • [6] Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Untch, M
    Lisboa, B
    Kohler, G
    Diergarten, K
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (05) : 35 - 39
  • [7] Phase III study of vinorelbine plus epirubicin versus epirubicin alone in first-line chemotherapy of metastatic breast cancer:: An Scandinavian breast group study (SBG9403)
    Ejlertsen, B
    Mouridsen, HT
    Langkjer, ST
    Andersen, J
    Sjöström, J
    Kjaer, M
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 : S19 - S19
  • [8] Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: A central European cooperative oncology group international, multicenter, prospective, randomized phase III trial
    Zielinski, C
    Beslija, S
    Mrsic-Krmpotic, Z
    Welnicka-Jaskiewicz, M
    Wiltschke, C
    Kahan, Z
    Grgic, M
    Tzekova, V
    Inbar, M
    Cervek, J
    Chernozemsky, I
    Szanto, J
    Spanik, S
    Wagnerova, M
    Ghilezan, N
    Pawlega, J
    Vrbanec, D
    Khamtsov, D
    Soldatenkova, V
    Brodowicz, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) : 1401 - 1408
  • [9] Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Kcnecny, G
    Hecker, D
    Diergarten, K
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (01) : S13 - S16
  • [10] First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study
    Feher, O
    Vodvarka, P
    Jassem, J
    Morack, G
    Advani, SH
    Khoo, KS
    Doval, DC
    Ermisch, S
    Roychowdhury, D
    Miller, MA
    von Minckwitz, G
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (06) : 899 - 908
12345